Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 19:28 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Effect of Saxagliptin and Dapagliflozin on Endothelial Progenitor Cell in Patients With Type 2 Diabetes Mellitus
NCT03660683 · Sabyasachi Sen · PHASE4 · terminated · last registry update 2023-06-05 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Sponsor did not want to continue funding the study” | – | Registry record, Sabyasachi Sen |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SLC5A2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-05-22Phase 3 first posted: Boehringer Ingelheim, vicadrostat + empagliflozin (NCT06424288)
- 2024-05-16Phase 3 first posted: Shenzhen HighTide Biopharmaceutical Ltd., HTD1801 + Dapagliflozin (NCT06415773)
- 2024-05-08Phase 3 first posted: Beni-Suef University, Metformin + Dapagliflozin (NCT06405178)
- 2024-03-19Phase 3 first posted: Kirby Institute, Dapagliflozin 10mg Tab + Pitavastatin 4 Mg Oral Tablet (NCT06317051)
- 2024-03-13Phase 3 first posted: AstraZeneca, balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg + balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg (NCT06307652)
- 2024-02-20Phase 3 first posted: AstraZeneca, Baxdrostat/dapagliflozin + Dapagliflozin in combination with placebo (NCT06268873)
- 2024-01-05Phase 3 first posted: Eli Lilly and Company, Orforglipron + Dapagliflozin (NCT06192108)
- 2023-12-18Phase 3 first posted: Ottawa Heart Institute Research Corporation, Dapagliflozin 10mg Tab (NCT06174753)
- 2023-11-29Phase 3 first posted: University of Minnesota, Empagliflozin (NCT06149793)
- 2023-11-03Phase 3 first posted: Sohag University, SGLT2 inhibitor (NCT06117137)
- 2023-10-18Phase 3 first posted: AstraZeneca, Zibotentan/Dapagliflozin + Dapagliflozin (NCT06087835)
- 2023-09-11Phase 3 first posted: Chulalongkorn University, Empagliflozin 10 MG + Placebo (NCT06030843)
- 2023-09-06Phase 3 first posted: Colorado Prevention Center, Finerenone + Empagliflozin (NCT06024746)
- 2023-08-14Phase 3 first posted: Mostafa Bahaa, Mesalamine + Dapagliflozin 10mg Tab (NCT05986136)
- 2023-07-13Phase 3 first posted: University Hospital Goettingen, Dapagliflozin + Placebo (NCT05944016)
- 2023-03-10Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, Dapagliflozin propanediol (FORXIGA™/FARXIGA™1) + Placebo comparator (NCT05764057)
- 2023-02-08Phase 3 first posted: University Health Network, Toronto, Empagliflozin 25 MG (NCT05715814)
- 2023-01-03Phase 3 first posted: Tanta University, Empagliflozin + olanzapine (NCT05669742)
- 2022-11-01Phase 3 first posted: Beni-Suef University, Dapagliflozin 5 MG + Metformin Hydrochloride 1000 MG (NCT05601336)
- 2022-07-21Phase 3 first posted: The George Institute, Dapagliflozin 10mg Tab + Placebo (NCT05468203)
- 2022-06-22Phase 3 first posted: Ottawa Heart Institute Research Corporation, Canagliflozin + Placebo (NCT05427084)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision